Abbott Laboratories reported $45.1B of revenue over the trailing twelve months, +6.6% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $45.1B (to Q1 2026). Net income: $6.28B, trailing twelve months to Q1 2026. Free cash flow: $7.38B, trailing twelve months to Q1 2026. Operating margin: 17%, trailing twelve months to Q1 2026.

ABTAbbott Laboratories

Healthcare

$99.59-25% 1Y

$99.59

$82.5652 weeks$134.49

ABT as reported

Abbott Laboratories reported $45.1B of revenue over the trailing twelve months, +6.6% on the year before. 11 reported series are charted on this page, each one as filed.

$45.1B

Revenue, trailing twelve months · to Q1 2026 · +6.6% against the twelve months before

Net income: $6.28B
Net income · −54% year on year · trailing twelve months to Q1 2026
Free cash flow: $7.38B
Free cash flow · +11% year on year · trailing twelve months to Q1 2026
Operating margin: 17%
Operating margin · trailing twelve months to Q1 2026

Details›

Every series Ryufin has for ABT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$45.1B	+6.6%	Q1 2026
Net income	$6.28B	−54%	Q1 2026
EPS	$3.58	−54%	Q1 2026
Gross margin	56%	n/a	Q1 2026
Operating margin	17%	n/a	Q1 2026
Net margin	14%	n/a	Q1 2026
ROE	20%	n/a	Q1 2026
ROA	12%	n/a	Q1 2026
ROIC	10%	n/a	Q1 2026
Free cash flow	$7.38B	+11%	Q1 2026
P/E	27.8	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.